Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 4Rectal Neoplasms 2Prostatic Neoplasms 2Lung Neoplasms 2Leukemia 2Esophageal Neoplasms 2Colorectal Neoplasms 2Colonic Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms, Male 2Adenocarcinoma Of Esophagus 2Triple Negative Breast Neoplasms 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Oligodendroglioma 1Multiple Myeloma 1Liposarcoma 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Kidney Neoplasms 1Gliosarcoma 1Glioma, Subependymal 1Glioma 1Glioblastoma 1Esophageal Squamous Cell Carcinoma 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

Sunitinib 19Everolimus 17Bevacizumab 13aldesleukin 11Sorafenib 11Interleukin-2 10Cyclophosphamide 10Axitinib 10Nivolumab 9fludarabine phosphate 7fludarabine 7pembrolizumab 5Gemcitabine 5temsirolimus 4pazopanib 4Ipilimumab 4peginterferon alfa-2b 3durvalumab 3cabozantinib 3Radiosurgery 3Interferon-alpha 3Granulocyte-Macrophage Colony-Stimulating Factor 3Filgrastim 3Erlotinib Hydrochloride 3Cryosurgery 3vandetanib 2spartalizumab 2perflutren 2ixabepilone 2chiron 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Kidney Neoplasms × Reverse Transcriptase Polymerase Chain Reaction × Clear all
NCT00589550 2015-06-08

PEG-Interferon Alfa-2b and Sorafenib in Treating Patients With Unresectable or Metastatic Kidney Cancer

Ohio State University Comprehensive Cancer Center

Phase 1 Terminated
1 enrolled 2 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡